Jupiter Neurosciences Appoints Dr. Tomas J. Philipson as Board Director with FDA and Health Economics Background

Jupiter Neurosciences has added a health economist with direct FDA and White House advisory experience to its Board of Directors, a signal that the clinical-stage company is positioning its governance structure to handle the regulatory and reimbursement complexity ahead of any potential approval pathway. Dr. Tomas J. Philipson joined the board effective June 26, 2026, and will sit on both the Audit Committee and Compensation Committee.

Philipson's government record spans senior economic advisory roles at the FDA and the Centers for Medicare & Medicaid Services in 2003–2004, membership on the Key Indicator Commission of the U.S. Congress in 2012, and service as Acting Chairman of the White House Council of Economic Advisers from June 2019 to June 2020. That last role placed him at the centre of executive-branch deliberations on biopharmaceutical pricing and market access policy during a period of significant regulatory activity.

His academic base is the University of Chicago, where he holds the Daniel Levin Chair of Public Policy Emeritus with cross-appointments in Economics, the Law School, and the Harris School of Public Policy. His research has directly informed pharmaceutical valuation methodologies, a discipline with growing relevance as payers apply health technology assessment frameworks more rigorously to novel neurological therapies.

On the private-sector side, Philipson co-founded Precision Health Economics LLC in 2007, which was acquired in 2015, and has since operated TJP Economic Consulting Inc., advising senior biopharmaceutical executives on economic and policy strategy. He currently serves as Managing Partner of MEDA Ventures and holds advisory positions across several health and life sciences organisations, including Diagnos Inc. and GATC Health Corp.

For regulatory affairs and market access teams tracking clinical-stage neuroscience companies, the appointment reflects a broader industry pattern: boards are increasingly integrating health economics expertise earlier in development, before pivotal trial readouts, to shape reimbursement narratives and engage payers in parallel with FDA interactions. Jupiter Neurosciences has not disclosed the specific programme milestones that prompted the governance change at this stage.

The practical test of Philipson's contribution will come when Jupiter Neurosciences advances toward a regulatory submission and the board's economic and policy framing is stress-tested against payer requirements and agency expectations.

Source: Jupiter Neurosciences via GlobeNewswire, July 7, 2026.